Cargando…

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up

Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dixon, Dave L, Buckley, Leo F, Trankle, Cory R, Kadariya, Dinesh, Abbate, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513834/ https://www.ncbi.nlm.nih.gov/pubmed/28744103 http://dx.doi.org/10.2147/DDDT.S114091

Ejemplares similares

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

2363: Ventriculo-arterial coupling and left ventricular mechanical work in systolic and diastolic heart failure
por: Buckley, Leo, et al.
Publicado: (2018)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction
por: Trankle, Cory, et al.
Publicado: (2017)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
por: Toth, Peter P., et al.
Publicado: (2017)

Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction
por: Buckley, Leo F., et al.
Publicado: (2018)

Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction
por: Carbone, Salvatore, et al.
Publicado: (2017)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study
por: Gupta, Milan, et al.
Publicado: (2022)

3415 Percent Predicted Peak Exercise Oxygen Pulse Is a Marker of Cardiac Reserve Following Thoracic Radiotherapy
por: Canada, Justin McNair, et al.
Publicado: (2019)

2544: Dietary polyunsaturated fatty acid consumption is associated with improved body composition in nonalcoholic steatohepatitis patients
por: Billingsley, Hayley, et al.
Publicado: (2018)

Influence of extracellular volume fraction on peak exercise oxygen pulse following thoracic radiotherapy
por: Canada, Justin M., et al.
Publicado: (2022)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction
por: van Wezenbeek, Jessie, et al.
Publicado: (2018)

Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF: The UFA-Preserved Pilot Study
por: Carbone, Salvatore, et al.
Publicado: (2019)

Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study
por: Al Faraidy, Khalid, et al.
Publicado: (2023)

Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
por: van Bruggen, Folkert H., et al.
Publicado: (2021)

2390: Cardiac abnormalities drive exercise intolerance in patients with nonslcoholic fatty liver disease
por: Canada, Justin M., et al.
Publicado: (2018)

2438: Dose-dependent nature of cocaine infusions on cardiovascular hemodynamics
por: Carbone, Salvatore, et al.
Publicado: (2018)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

EVOLOCUMAB TREATMENT FAILURE FOLLOWING COVID-19 MRNA VACCINATION
por: Park, Byung Joon, et al.
Publicado: (2022)

Mitochondrial Membrane Permeability Inhibitors in Acute Myocardial Infarction: Still Awaiting Translation
por: Trankle, Cory, et al.
Publicado: (2016)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
por: Del Buono, Marco Giuseppe, et al.
Publicado: (2022)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Ventriculoseptal Rupture Caused by Takotsubo Syndrome
por: Sternberg, Michael E., et al.
Publicado: (2020)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)

A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers
por: Wohlford, George F., et al.
Publicado: (2021)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
por: Inoue, Ikuo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m97jbipra2pj26cjgfatn9ahbv